The Global Kidney Cancer Drugs Market, by Therapy Class (Targeted Therapy, Immunotherapy and Chemotherapy), by Pharmacological Class (Angiogenesis Inhibitors, mTOR Inhibitors, Cytokines and Others (Immune Checkpoint Inhibitors, CTLA-4 inhibitors, Antimetabolites and Others)), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 4.6 billion in 2018, and is projected to exhibit a CAGR of 6.4% during the forecast period (2018 – 2026).
Various key drug manufacturers are increasingly gaining regulatory drug approval for the treatment of renal cell carcinoma. These key players are launching novel and superior drug candidates in the market to capture more market share. Growing launch of innovative drugs for the treatment of renal cell carcinoma will fuel the growth of market during the forecast period.
For instance, in April 2018, U.S. Food and Drug Administration (FDA) approved Bristol-Myers Squibb Company’s Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg, injections for intravenous use, as the first immuno-oncology combination therapy for previously untreated patients with intermediate, and poor-risk advanced renal cell carcinoma (RCC). The combination decreased the risk of death by 37 percent compared to Sutent: a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma (RCC) and the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. In December 2017, the U.S. FDA granted regular approval to Exelixis, Inc.’s cabozantinib (Cabometyx) as a first line treatment for patients with advanced renal cell carcinoma (RCC). In 2016, FDA approved Cabometyx for treatment of patients with advanced RCC who received prior anti-angiogenic therapy.
Browse 25 Market Data Tables and 29 Figures spread through 173 Pages and in-depth TOC on ‘Kidney Cancer Drugs Market, by Therapy Class (Targeted Therapy, Immunotherapy and Chemotherapy), by Pharmacologic Class (Angiogenesis Inhibitors, mTOR Inhibitors, Cytokines and Others (Immune Checkpoint Inhibitors, CTLA-4 inhibitors, Antimetabolites and Others)), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026’
To know the latest trends and insights prevalent in the kidney cancer drugs market, click the link below:
Furthermore, key players are focusing on product development through strategic collaborations and commercial expansion in emerging markets. This could lead to make market more competitive, increase revenue growth of key players, and offer lucrative growth outlook during the forecast period. Biosimilar development is gaining traction as a promising market opportunity in kidney cancer therapeutics. Several biotech companies launched Avastin biosimilars across several cancer indications in emerging markets such as India, Russia, and Argentina. For instance, in November 2017, Biocon Ltd. launched its biosimilar, bevacizumab, for the treatment of several types of cancer, under the brand name Krabeva in India, in 100 mg/4 ml vials and 400 mg/16 ml vials formulation. Krabeva is indicated as a first-line treatment for patients with metastatic colorectal cancer and used to treat lung, kidney, cervical, ovarian, and brain cancers.
Key Takeaways of the Kidney Cancer Drugs Market: